2-(4-formylphenoxy)-N,N-dimethylacetamide | 1017021-56-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(4-formylphenoxy)-N,N-dimethylacetamide
• CAS: 1017021-56-5
• 化学式: C₁₁H₁₃NO₃
• mdl: MFCD09942943
• 分子量: 207.229
• InChiKey: YLJFPXRGJPDBOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4-formylphenoxy)-N,N-dimethylacetamide 、 (4-oxazol-5-yl-phenyl)-hydrazine 以 乙醇 为溶剂， 反应 4.0h， 生成 N,N-Dimethyl-2-{4-[4-(oxazol-5-yl)phenylhydrazonomethyl]phenoxy}acetamide
  参考文献：
  名称：

  EP1612204

  摘要：

  公开号：
• 作为产物：
  描述：

  二甲胺 、 4-甲酰苯氧基乙酸 在 氯化亚砜 、 N,N-二甲基甲酰胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 51.0h， 生成 2-(4-formylphenoxy)-N,N-dimethylacetamide
  参考文献：
  名称：

  [EN] 2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY
  [FR] DÉRIVÉS DE 2-PHÉNYL-3H-IMIDAZO[4,5-B]PYRIDINE UTILISÉS COMME INHIBITEURS DE L'ACTIVITÉ DE LA TYROSINE KINASE DE MAMMIFÈRE ROR1

  摘要：

  化合物的化学式（I´）或（I´´）或其药学上可接受的盐。该化合物是哺乳动物激酶酶活性的抑制剂，包括ROR1酪氨酸激酶活性，并可用于治疗与该活性相关的疾病。

  公开号：

  WO2016124553A1

文献信息

• [EN] INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME<br/>[FR] INHIBITEURS DU COMPLEXE D'ACTIVATION DE TRANSCRIPTION DU RÉCEPTEUR NOTCH ET PROCÉDÉS D'UTILISATION DE CES DERNIERS
  申请人：UNIV MIAMI

  公开号：WO2016154255A1

  公开（公告）日：2016-09-29

  Disclosed herein are inhibitors of the Notch transcriptional activation complex, and methods for their use in treating or preventing diseases, such as cancer. The inhibitors described herein can include compounds of Formula (I) and pharmaceutically acceptable salts thereof: Formula (I), wherein the substituents are as described.

  本文披露了Notch转录激活复合物的抑制剂，以及它们在治疗或预防疾病（如癌症）中的使用方法。本文描述的抑制剂可以包括式（I）的化合物及其药用可接受盐：式（I），其中取代基如所述。
• [EN] PYRROLOPYRIMIDINE DERIVATIVES USEFUL AS MODULATORS OF MULTIDRUG RESISTANCE<br/>[FR] DERIVES DE PYRROLOPYRIMIDINE POUVANT ETRE UTILISES EN TANT QUE MODULATEURS DE LA MULTIRESISTANCE AUX MEDICAMENTS
  申请人：XENOVA LTD

  公开号：WO2004065389A1

  公开（公告）日：2004-08-05

  A compound which is a pyrrolopyrimidine of formula (I) wherein: R1 is selected from R9 and halogen; R2 is NR6R7; R3 is selected from H, C1-C6 alkyl which is unsubstituted or substituted and -(CH2) nAr; R4 is selected from H, C1-C6 alkyl and -(CH2)„ Ar; or R3 and R4 form, together with the N and C atoms to which they are attached, a fused five-, six-, seven- or eight-membered N-containing saturated ring which is unsubstituted or substituted; R5 is selected from CN, C02R9, C(O)NR10R11, -(CH2)nOH, -(CH2)nR10Rn, -C=CH, -C(S)NR10R11, -C(NH2)=NOR9, -C(R9)=NOR9, -C(NH2)NH, -C(O)R9 and an unsaturated 5- or 6-membered heterocyclic group which contains 1, 2 or 3 heteroatoms selected from N, O and S and which is unsubstituted or substituted; R6 and R7, which are the same or different, are selected from C1-C6 alkyl which is unsubstituted or substituted, -(CH2)nX and -(CH2)nAr; or R6 and R7 form, together with the nitrogen atom to which they are attached, a saturated five-, six-, seven- or eight-membered heterocyclic group which contains one nitrogen atom and 0 or from 1 to 3 additional heteroatoms selected from N, O and S, which is unsubstituted or substituted and which optionally contains one or two bridgehead atoms; R10 and R11, which are the same or different, are selected from H, C1-C6 alkyl which is unsubstituted or substituted, -(CH2)nC3-C10 cycloalkyl and -(CH2) nAr; or R10 and R11 form, together with the nitrogen atom to which they are attached, a saturated five or six membered heterocyclic group which contains a nitrogen atom and 0 or from to 3 additional heteroatoms selected from O, S and N, which is unsubstituted or substituted and which is optionally fused to a benzene ring which is unsubstituted or substituted; n is the same or different when more than one is present within a given substituent group and is 0 or an integer of from 1 to 6; X is selected from -CN, -C02R9 and -NR10R11; R9 is the same or different when more than one is present within a given substituent group and is selected from -H, -QAr, -(CH2) nAr, C1-C6 alkyl which is unsubstituted or substituted and -(CH2) nC3-C10cycloalkyl, wherein the cycloalkyl moiety is optionally fused to a benzene ring which is unsubstituted or substituted; Q is C2-C6 alkenylene or alkynylene; and Ar is an unsaturated C6-C10 membered carbocyclic group or an unsaturated 5-11 membered heterocyclic group, which groups are unsubstituted or substituted; or a pharmaceutically acceptable salt thereof. These compounds have activity as inhibitors of MRP (multidrug resistant protein) and may thus be used to modulate multidrug resistance, for instance in potentiating the cytotoxicity of a chemotherapeutic agent.

  一种具有以下结构式(I)的吡咯吡嘧啶化合物，其中：R1从R9和卤素中选择；R2为NR6R7；R3从H、未取代或取代的C1-C6烷基和-(CH2) nAr中选择；R4从H、C1-C6烷基和-(CH2) nAr中选择；或者R3和R4与它们连接的N和C原子一起形成未取代或取代的融合的含氮饱和环，该环为五、六、七或八元环；R5从CN、C02R9、C(O)NR10R11、-(CH2)nOH、-(CH2)nR10Rn、-C=CH、-C(S)NR10R11、-C(NH2)=NOR9、-C(R9)=NOR9、-C(NH2)NH、-C(O)R9和一个含有1、2或3个异原子（N、O和S）且未取代或取代的不饱和5-或6元杂环基中选择；R6和R7相同或不同，从未取代或取代的C1-C6烷基、-(CH2)nX和-(CH2)nAr中选择；或者R6和R7与它们连接的氮原子一起形成含有一个氮原子和0或1至3个额外异原子（N、O和S）的饱和五、六、七或八元杂环基，该环未取代或取代，可选地包含一个或两个桥头原子；R10和R11相同或不同，从未取代或取代的H、C1-C6烷基、-(CH2)nC3-C10环烷基和-(CH2)nAr中选择；或者R10和R11与它们连接的氮原子一起形成含有一个氮原子和0或1至3个额外异原子（O、S和N）的饱和五或六元杂环基，该环未取代或取代，可选地与未取代或取代的苯环融合；n在给定取代基中的多个存在时相同或不同，为0或1至6的整数；X从-CN、-C02R9和-NR10R11中选择；R9在给定取代基中的多个存在时相同或不同，从-H、-QAr、-(CH2)nAr、未取代或取代的C1-C6烷基和-(CH2)nC3-C10环烷基中选择，其中环烷基部分可选地与未取代或取代的苯环融合；Q为C2-C6烯基或炔基；Ar为未取代或取代的不饱和C6-C10环烷基或不饱和5-11元杂环基，或其药学上可接受的盐。这些化合物具有作为MRP（多药耐药蛋白）抑制剂的活性，因此可用于调节多药耐药性，例如增强化疗药物的细胞毒性。
• Beta-alanine derivatives and their use as receptor anatgonists
  申请人：——

  公开号：US20030018193A1

  公开（公告）日：2003-01-23

  A beta-alanine derivative of the formula (I) wherein R 1 is hydrogen atom or an amino protective group; A is a lower alkylene group or a lower alkenylene group; R 2 is hydrogen atom or an amino group which may be substituted with an acyl group; R 3 is hydrogen atom or an aryl or aralkyl group which may be substituted with one or more of hydroxy and/or lower alkoxy, a moiety represented by the formula (II), which is a bivalent N-containing 6- to 8-membered heterocyclic group, or a pharmaceutically acceptable salt thereof.

  公式（I）的β-丙氨酸衍生物，其中R1是氢原子或氨基保护基团；A是较低的烷基或较低的烯基基团；R2是氢原子或氨基团，可能被酰基取代；R3是氢原子或芳基或芳基基团，可能被一个或多个羟基和/或较低的烷氧基取代，由公式（II）表示的基团，该基团是一种双价的含氮6-到8-成员杂环基团，或其药用盐。
• Inhibitors of the Notch transcriptional activation complex and methods for use of the same
  申请人：UNIVERSITY OF MIAMI

  公开号：US10501413B2

  公开（公告）日：2019-12-10

  Disclosed herein are inhibitors of the Notch transcriptional activation complex, and methods for their use in treating or preventing diseases, such as cancer. The inhibitors described herein can include compounds of Formula (I) and pharmaceutically acceptable salts thereof: Formula (I), wherein the substituents are as described.

  本文公开了 Notch 转录激活复合物的抑制剂，以及将其用于治疗或预防癌症等疾病的方法。本文所述的抑制剂可包括式（I）化合物及其药学上可接受的盐类：式 (I)，其中取代基如所述。
• 2-phenyl-3H-imidazo[4,5-B]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
  申请人：Kancera AB

  公开号：US10550113B2

  公开（公告）日：2020-02-04

  A compound of formula (I′) or (I″) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.

  式（I′）或（I″）化合物或其药学上可接受的盐。该化合物是哺乳动物激酶酶活性（包括 ROR1 酪氨酸激酶活性）的抑制剂，可用于治疗与此类活性相关的疾病。